PRESS IN THE NEWS July 1 2020 EpicentRx Inc. and SciClone Pharmaceuticals Establish Licensing Agreement for RRx-001 in Greater China June 10 2020 EpicentRx Appoints Life Sciences Investment Banking Veteran, Dr. Franck Brinkhaus, as President and Chief Financial Officer May 29 2020 EpicentRx Appoints Oncologist Tony Reid, M.D., Ph.D., as Chief Executive Officer (CEO) March 3 2020 EpicentRx IND Application for Second Immuno-oncology Program, a TGF-β Trap Adenovirus, Receives FDA Clearance December 4 2019 EpicentRx Appoints Senior Life Science Financial Executive Dr. Franck Brinkhaus as Chief Financial Officer November 25, 2019 EpicentRx Announces Positive Results From Phase 1 Trial of RRx-001 as First-line Treatment in Newly Diagnosed Glioblastoma November 13, 2019 EpicentRx Closes $35 million Series D Financing to Support Development of Small Molecule Immunotherapy and Oncolytic Viral Platform November 05, 2019 EpicentRx Initiates Dosing in Phase 3 Trial of Immunotherapy RRx-001 for Third-line Small Cell Lung Cancer June 25, 2019 EpicentRx Announces Publication of Its Positive Phase 2 3rd Line SCLC Results With RRx-001 Plus a Platinum Doublet in the British Journal of Cancer (BJC) May 02, 2018 First Patient Treated With Next-Generation Immunotherapy at UC Cincinnati May 02, 2018 EpicentRx Announces First Ever Treatment of Cancer Patient with Personalized, Custom-Made Viral Vaccines August 19, 2015 EpicentRx Announces Publication of Phase 1 Trial Results for the Anti-Cancer Agent, RRx-001, in Lancet Oncology August 09, 2018 Radioprotectors: Defensive Weapons In The War On Cancer
